NDAORALSOLUTION
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
2
Mechanism of Action
Iron Chelating Activity
Pharmacologic Class:
Iron Chelator
Clinical Trials (2)
Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
Started Jan 2012
0Acute Kidney Injury
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
Started Jun 2010
60 enrolled
Contrast-Induced Acute Kidney Injury
Loss of Exclusivity
LOE Date
Oct 26, 2029
44 months away
Patent Expiry
Oct 26, 2029
Exclusivity Expiry
Apr 30, 2028
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8703156 | Oct 26, 2029 | Product | U-3083 |